Long-term evaluation of safety and biological effects of Korean Red Ginseng (*Panax Ginseng*): a long-term in vivo study

Soo Kyung Park¹, Sung-Won Kim¹, Hwi Won Seo², Sun Hee Hyun¹, Jong-Su Kyung¹, Soo-Hyun Youn¹, Seung Ho So¹, Gyo In¹, Chae-Kyu Park¹, Eugene C. Yi³, Chang-Kyun Han¹ and Yong Yook Lee¹*

**Abstract**

**Background** Although Korean Red Ginseng (KRG) is safe, this finding was only evaluated in 3-mo-long studies. Its safety was verified through a 6-mo KRG administration clinical study, but long-term studies beyond 6 mo are insufficient. This study investigated the safety and efficacy of 12-mo KRG administration.

**Methods** In this study, 300 mg/kg of KRG was administered to male and female Sprague Dawley rats for 4, 8, and 12 mo to evaluate its efficacy and safety. Clinical signs, including pathological examination and haematological analyses, were observed. Flow cytometric analyses were utilised to analyse spleen and thymus immune cell counts after 12 mo. Proteomic analysis of the sera was performed using a nanospray-interfaced mass spectrometer with an 11-plex Tandem Mass Tag (TMT) labelling system. Bioinformatic analysis was then performed using Ingenuity Pathway Analysis and PANTHER. Data are available via ProteomeXchange with identifier PXD032036.

**Results** No significant body and organ weight changes were observed, and haematological and serum biochemical analyses did not show clinical significance. The effectiveness of long-term KRG administration was confirmed through increased immune cell distribution and activity. Changes in proteins correlated with viral infection reduction were confirmed through proteomic analysis.

**Conclusion** The results suggested that 12-mo KRG intake is safe, improves immune system activity, and reduces viral infections with no significant changes in toxicological aspects.

**Keywords** Immunity, Korean Red Ginseng, Proteomics, Safety
Background

The development of clinical services has led to increased life expectancy in recent decades by controlling diverse diseases [1]. Specifically, the global population’s lifestyle changes and income increased interest in health issues, such as non-communicable diseases. For infectious diseases like COVID-19, the lack of a cure or vaccine motivated consumers to protect themselves and improve their immune systems by adopting functional foods and healthier diets [2]. Notably, the demand for functional foods in the global market, including those with natural products, has increased to help consumers sustain a healthy lifestyle [3]. Food safety has become a significant issue with a growing functional food market because adverse reactions have also increased. Natural product safety is a significant concern because these formulations contain various ingredients, making it difficult to predict their toxicity after administration [4].

Korean Red Ginseng (KRG), or processed Panax ginseng Meyer, is indigenous to Korea. It has gained six approvals from the Korean Food and Drug Administration (KFDA) as a functional food for improving immune function, antioxidant activity, memory, blood circulation, and fatigue recovery. Safety studies related to KRG have reported no serious side effects when consuming KRG, noting that symptoms were mild and temporary [5]. However, most KRG safety experiments were only evaluated for short-term safety or 12 wk [5], and only one long-term clinical study evaluated KRG safety for 24 wk [4]. However, studies on more long-term safety are insufficient, and efficacy studies related to this are necessary to ensure the reliability of KRG. Therefore, this study evaluates the long-term safety and efficacy of KRG by administering 300 mg/kg of KRG to Sprague-Dawley rats for 4, 8, and 12 mo. The body and organ weight changes were investigated through haematological and serum biochemical analyses and pathological examinations. In addition, proteomic analysis was used to confirm the effectiveness of long-term KRG administration and evaluate immune cell classification and activity. The authors confirm that the study was reported according to the ARRIVE guidelines.

Materials and methods

KRG water extract and general chemicals

KRG was prepared using a 6-yr-old ginseng extract prepared by the Korea Ginseng Corporation following the ISO 19610 international standard production process. Ammonium bicarbonate (ABC), dithiothreitol (DTT), iodoacetamide (IAA), and urea were purchased from Merck (MO, USA). Meanwhile, trypsin (MS grade) was obtained from Thermo Fisher Scientific (IL, USA).

Long-term safety study

Test conditions and experimental specimens

A total of 120 4-wk-old male and female, specific pathogen-free (SPF) Sprague-Dawley (SD) rats were obtained from Koatech Inc. (Pyeongtaek-si, Korea). Before administration, the rats were acclimatised for 7 d by being housed in polycarbonate plastic cages (1 rat per cage) with aspen porous good laboratory practice (GLP) bedding (Samtako, Osan-si, Korea) in a room with controlled temperature (22°C±3°C), humidity (50%, 50%±20%), and a 12-h light/dark cycle. The rats were fed with standard rodent chow (Purina, USA) and filtered water ad libitum. At five weeks old, the rats were divided into 12 groups randomly (10 males and 10 females per group), which included male and female vehicle controls (distilled water) and a KRG-treated group (300 mg/kg/day). Figure 1 shows the groups used in the study, which mainly consist of 4 groups (2 control and 2 KRG groups for males and females) for each duration (4, 8, and 12 mo).

Body and organ weight changes

The rats’ body weights were measured weekly from the first day of administration to the day of necropsy. Organs, including the brain, heart, lung, liver, spleen, kidney, adrenal gland, testis, and uterus, were dissected, and their absolute weights were measured. Relative organ weight was calculated as the ratio between the absolute organ weight and the body’s weight before necropsy.

Food consumption changes

Food consumption was measured weekly during the mid and late experimental study from weeks 18 to 50. Daily food consumption (g/rat/day) was calculated as the difference between the newly supplied food and the remaining food for the next day.

Analytical tests

Biochemistry and haematology

Before necropsy, all rats were fasted overnight and euthanised by exsanguination under isoflurane anaesthesia after recording their body weights. Blood samples were drawn from the inferior vena cava, collected in ethylenediaminetetraacetic acid (EDTA) vacutainers, and analysed for white blood cell (WBC) count, red blood cell (RBC) count, haemoglobin (Hb), haematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), and platelet (PLT) count using a blood cell counter (MS9-5, Melet Schloesing Laboratories, France). For clinical biochemistry analyses, serum was obtained from blood collected in EDTA-free vacutainers by centrifugation at 3,000rpm for 10min. An automatic biochemical analyser (7100, HITACHI, Japan)
was used to analyse the following in the blood samples: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine (CREA), total protein (TP), albumin (ALB), albumin-globulin (A/G) ratio, total cholesterol (T-CHO), triglyceride (TG), and glucose (GLU). The remnant serum was stored at $-78^\circ$C until the global proteomic profiling analysis was performed.

**Flow cytometry analysis for immune cells 12-months KRG administration**

After the rats were euthanised after 12 mo of administration, their spleens and thymi were collected and placed in an ice-cooled Roswell Park Memorial Institute (RPMI) medium. The prepared spleens were filtered with a 40 mm nylon mesh, the supernatant was removed by centrifugation, and 2 mL of ACK lysis buffer was added. Then, 5 mL of RPMI 1640 medium was added and centrifugally washed twice (1200 rpm, 5 min, 4°C). The procedure for flow cytometric analysis follows the method of Kim et al. [6]. During analysis of the population of immune cells, the cells were washed with FBS strain buffer (BD Pharmingen™) and incubated with anti-rat CD32 for 20 min at 4°C to prevent nonspecific binding. The cells were incubated with the following fluorochrome-conjugated antibodies specific for FITC Mouse Anti-Rat CD45R, PE Mouse Anti-Rat CD4, PerCP Mouse Anti-Rat CD8a, FITC Mouse Anti-Rat Granulocytes, PE Mouse Anti-Rat RT1B, PE-Cy™5 Mouse Anti-Rat CD4, FITC Mouse Anti-Rat CD25, FITC Mouse Anti-Rat CD161a, PE Mouse Anti-Rat IFN-γ (BD Bioscience), CD3 Monoclonal Antibody (Invitrogen), and PE anti-mouse/rat/human FOXP3 Antibody (Biolegend). Next, the samples were washed with phosphate-buffered saline (PBS) 3 times. CytoFLEX (Beckman Coulter, Brea, CA, USA) was used to analyse the resulting samples using the stained cells per 10,000 cells. The data were analysed using FlowJo software (Tree Star Software, San Carlos, California, USA).

**Histopathology**

Each rat’s dissected organs were trimmed and observed macroscopically after 12 mo of KRG administration. The heart, lung, liver, spleen, and kidneys were fixed in 10% neutral buffered formalin. After paraffin infiltration using a tissue processor, the organs were embedded in paraffin, cut into 4 μm sections, stained with haematoxylin and eosin, and examined under a light microscope (Olympus BX50, Japan).

**Statistical analysis**

The results are presented as the mean±SEM. Data from body weights, food consumption, organ weights, blood biochemistry, and haematology indices were analysed using a student’s t-test or the Mann-Whitney test of the SPSS software program. The results were considered statistically significant at a value of $p<0.05$. 

---

**Fig. 1** Schematic chart of Korean Red Ginseng (KRG) administration. Rats were divided into 3 groups (10 males or females per group) per duration (G1: 4 mo, G2: 8 mo, G3: 12 mo). The KRG groups received 300 mg/kg doses per day.
Global proteomic profiling analysis

**Immunodepletion of abundant proteins with immunoglobulin Y (IgY)-R7 cartridge**

Six biological replicates among the 12 mo KRG administration and control groups were individually prepared for all six conditions, following the manufacturer’s instructions. For each serum sample, immunodepletion of the seven most abundant proteins (serum albumin, immunoglobulin G (IgG), fibrinogen, transferrin, immunoglobulin M (IgM), haptoglobin, and alpha1-antitrypsin) in rat serum was performed with a Seppro IgY-R7 spin cartridge (SEP130, Merck), containing most of the immobilised antibodies against the seven proteins. The collected flow-through sample’s seven-protein concentration was determined using a bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, IL, USA).

**Protein digestion and TMT 11-plex labelling**

Each depleted serum sample was denatured with 8M urea in 50 mM ammonium bicarbonate (ABC). Then, dithiothreitol (DTT) was added to each sample (now at 10 mM) and incubated for 1h at 37°C, and IAA was added (now at 40 mM) and incubated at the same temperature and duration. The sample was diluted with 50 mM ABC (pH 8.5) to become 1 M urea, and 1 mM calcium chloride (CaCl₂) and trypsin at a 1:50 trypsin to sample ratio (w/w) were added and incubated overnight at 37°C. The peptide sample was desalted using a C18 SPE cartridge (Merck) and subjected to a BCA assay. A subfraction (about 3 µg of peptide) from each sample was mixed into a single tube to prepare the pooled reference sample.

Four sets of samples using Tandem Mass Tag (TMT, Thermo Fisher Scientific) 11-plex labelling were prepared for system-wide quantitative comparison. Briefly, 5 µL of the peptide in each sample was obtained and labelled with the adequate TMT 11-plex reagent channel according to the manufacturer’s protocols. The TMT-labelled peptide samples in the same set were then combined (for a total of 55 µL of peptide sample) for further fractionation.

**Multidimensional mid-pH (pH 8) reverse-phase liquid chromatography (RPLC) fractionation**

In this step, microscale (25 µg) mid-pH reverse-phase liquid chromatography RPLC fractionation was performed using an in-house packed 200 µm I.D. A C18 capillary column nanoACQUITY ultra-performance liquid chromatography (UPLC; Waters) was utilised with a 3 µL/min flow rate. Meanwhile, using a linear gradient of solvent A (10 mM ABC in water) and solvent B (10 mM ABC in 90% acetonitrile (I)) caused an increase from 2 to 40% in the latter for 90min. The eluent was automatically collected and concatenated into 12 fractions using Triversa NanoMate (Advion, NY, USA).

**LC-MS3 experiment**

All four TMT-labeled plasma sample sets were analysed using an Orbitrap Fusion Lumos Tribrid mass spectrometer (MS; Thermo Fisher Scientific) in data-dependent synchronous precursor selection (SPS)-MS3 mode. The mass spectrometer was coupled with nanoACQUITY UPLC equipped with an in-house packed trap (150µm I.D. x 3cm) and analytical column (75 µm I.D. x 100 cm) using 3µm Jupiter C18 column particles (Phenomenex). In this step, the 10 most intense ions were isolated at 0.5 Thomson (Th) of precursor isolation width under an identical full MS scan setting for collision-induced dissociation (CID) with tandem mass spectrometry (MS/MS) in an ion trap with 4E3 of automatic gain control (AGC), 150 ms of maximum injection time (ITMax), and wide-band activation. The synchronous precursor selection (SPS)-based higher-energy collision dissociation (HCD) MS3 was performed by isolating the 10 most intense MS2 fragment ions using 2 m/z of isolation width, 1.5E5 of AGC, 250 ms of ITMax, and 55% of normalised collision energy (NCE).

**Database search, quantitative analysis, and bioinformatic analysis**

For the quantitative analysis of TMT-labeled rat plasma datasets, Proteome Discoverer (PD) ver. 2.3 (Thermo Fisher Scientific) was cross-referenced against the UniProt rat database proteome database (29,944 entries) using the following parameters: static carbamidomethylation of cysteine, dynamic oxidation of methionine, and dynamic TMT11 modification of peptide N-terminus and lysine. The resulting peptide hits were filtered with a 1% maximum false discovery rate (FDR) using the Percolator algorithm. The reporter ion ratios reported from PD were adjusted by applying the isotopic correction factors of the manufacturer’s TMT kit. Only reporter ions containing spectra were designated as “quantifiable spectra.” CID-MS2 spectra were used for peptide identification in this step, whereas HCD-MS3 spectra containing reporter ion signals were used for quantification. Based on the data, the evaluation of biological functions was performed using Ingenuity Pathway Analysis (IPA; Ingenuity Systems; Redwood City, CA, USA) and the PANTHER classification system.

**Results**

**Body and organ weight changes**

A total of 300 mg/kg of KRG was administered to Sprague Dawley rats for up to 12 mo. During the exposure period, noticeable mortality and clinical signs were not observed, and there were no statistically significant
body weight changes (Fig. S1). Aside from a decrease in the ovary’s weight, significant organ weight changes were not observed in relative organ weights (Table S1).

**Food consumption changes**
During the food consumption monitoring period from weeks 18 to 50, there were no significant differences in food consumption between KRG treatment and control groups for both male and female specimens (Fig. S2).

**Haematology and biochemistry**
There were no significant differences between the control and KRG-treated groups in the haematological analyses. MCV and MCHC significantly increased (p<0.05) in the 8 mo administration group’s female rats than in the control group. However, WBC count significantly decreased (p<0.05) in the male rats of the KRG group compared to the control group (Table 1). The AST levels in the male KRG administration group at 4 and 8 mo decreased significantly compared to the control group (p<0.05), and there was no significant difference in the female KRG administration group. Meanwhile, there was no significant difference in both male and female KRG administration groups at 12 mo. (Fig. 2a) CHO and TG levels tended to decrease compared to the control group, but there was no significant difference. However, BUN in the 12 mo and CREA in the 4 mo male KRG administration group decreased significantly (p<0.05) compared to the control group. In addition, the CPK level was significantly lower (p<0.05) in the 4 mo old male and female groups and the 12 mo old female KRG administration group (p<0.05).

**Flow cytometry analysis for immune cells**
Between the 12 mo KRG administration group and the control group, immune cell counts in rats were investigated to evaluate the immunological effects of long-term KRG administration (Fig. 2b). Flow cytometric analysis showed that after 12 mo of KRG administration, the ratio of thymic immune cells, including NK cells, dendritic cells (p<0.01) and Treg cells (p<0.05) in male rats, and T cells in both males (p<0.01) and females (p<0.05) significantly increased (Fig. 2b). Meanwhile, the splenic cell ratio increased, but there was no significant statistical significance. However, NK cell activity in the male spleen significantly increased (p<0.01).

**Histopathology**
A histopathological examination was performed between the 12 mo KRG administration and control groups using haematoyxlin and eosin (H & E)-stained samples (n=3). Scores were assigned according to the diagnosed degree’s grade, and numerical comparisons were performed with the average value (grade: minimal, slight, moderate, severe) to facilitate group-by-group comparison.

---

**Table 1** Haematological data for 4, 8, and 12 mo KRG administration (n = 8, mean ± SD)

| Month | Male | Female |
|-------|------|--------|
|       | WBC  | MCHC  |       | RBC  | MCH   |       | PLT   | MPV   |       |
| 4     | 32.7±1.07 | 0.3±0.05 | 32.5±0.73 | 0.3±0.05 | 17.6±0.57 | 0.3±0.05 | 56.7±0.57 | 0.3±0.05 | 12.6±0.57 |
| 8     | 30.1±0.64 | 0.3±0.05 | 29.1±0.64 | 0.3±0.05 | 16.7±0.64 | 0.3±0.05 | 55.6±0.64 | 0.3±0.05 | 12.6±0.64 |
| 12    | 30.1±0.64 | 0.3±0.05 | 29.1±0.64 | 0.3±0.05 | 16.7±0.64 | 0.3±0.05 | 55.6±0.64 | 0.3±0.05 | 12.6±0.64 |

---

**Figures**
- **Fig. 2a**
- **Fig. 2b**

---

**Notes**
- Table 1: Haematological data for 4, 8, and 12 mo KRG administration (n = 8, mean ± SD)
- Figures: 2a, 2b
Fig. 2  Blood biochemistry data and immune cell count changes for rats orally administered with Korean Red Ginseng (KRG). (a) Biochemical parameters of liver functions (aspartate transaminase (AST, U/L), alanine aminotransferase (ALT, U/L), and Alkaline phosphatase (ALP, U/L)); lipid parameters (total cholesterol (CHO, mg/dL), triglyceride (TG, mg/dL); the parameters of kidney functions (blood urea nitrogen (BUN, mg/dL), creatinine (CREA, mg/dL); and creatine phosphokinase (CPK, mg/dL) in KRG administered male and female rats. Results are expressed as mean±SD (n=8). (b) Changes in immune cell count for 12 mo KRG administration, showing splenic and thymic immune cell counts. Significant difference vs. control *(p<0.05), ***(p<0.01)
Compared to the control group, all toxicity-related results in the KRG administration tests for the male and female administration groups were identical (Fig. 3). Although spontaneous or ageing-related findings were observed in the male and female administration groups, similar severity and incidence results were observed in the control group. Because the findings were localised or unilateral, both were independent of KRG administration (Table S2).

Total proteomic analysis for identification of function
Global proteomic profiling analysis of rat sera was performed to identify differentially expressed proteins (DEPs) in rats administered with KRG for 12 mo (n=6). For quantitative analyses with protein identification, sera samples were labelled using 11-plex TMT agents, and the total identified protein list was compared with a 1% false discovery rate (FDR) level. A total of 493 unique proteins were identified through MS analysis for the male group and 466 for the female group using the target-decoy database (UniProt rat database) of Proteome Discoverer (Fig. 4a).

Next, the differentially expressed proteins (DEPs) with criteria under a level of $p<0.05$ (T-test) were selected (Table 2). Among the representative proteins chosen in the male rats, GM2A and SPP1 were upregulated, and SERPINA6 and TAGLN2 were downregulated. Otherwise, immunoglobulin (Ig)-like domain-containing proteins and Tf (HGNC:11,740) increased, and F10 (HGNC:3528) and FLNA (HGNC:3754) were lower in the female group. To identify the class and molecular functions of DEPs, a classification analysis of the proteins was performed using the PANTHER tool, which revealed that the proteins are classified into defence/immunity proteins (11), cytoskeletal proteins (12), and protein-binding activity modulators (9) in the male sera. In the

---

**Fig. 3** Histopathological changes in rats exposed to 12 mo KRG. (a) Male rats. (b) Female rats. (Haematoxylin and eosin, magnification: 200X, n=3)

**Fig. 4** Differentially expressed proteins (DEPs) in rats exposed to Korean Red Ginseng (KRG) and bioinformatic analysis after 12 mo KRG administration (n=6). (a) Volcano plot showing the $p$-value ($-\log_{10}p$) versus fold change ($\log_{2}$) of the proteomic analysis; (b) protein class and (c) molecular function analysis of DEPs by the Panther classification system; (d) selected decreased function of the DEPs in rats administered with KRG for 12 mo by IPA functional analysis (Red: biological process or disease in an upward trend; Green: biological process or disease is trending downward)
### Table 2
Differentially expressed up or downregulated proteins from male (a) and female (b) rat sera

| Description                                                                 | UniProt ID | Gene     | Location | Type(s)         | Log2 FC | p-value |
|----------------------------------------------------------------------------|------------|----------|----------|-----------------|---------|---------|
| H2A clustered histone 6                                                   | Q4FZT6     | H2AC6    | Nucleus  | other           | 1.436   | 0.008   |
| Heterogeneous nuclear ribonucleoprotein C, isoform CRAa                    | A0A0G2JXW4 |          |          |                 | 1.388   | 0.026   |
| Ig-like domain-containing protein                                         | D3ZEP5     |          |          |                 | 1.201   | 0.023   |
| Ig-like domain-containing protein                                         | D3ZAB3     |          |          |                 | 1.178   | 0.046   |
| Secreted phosphoprotein 1                                                 | P08721     | SPP1     | ES       | cytokine        | 1.139   | 0.006   |
| Tsukushi, small leucine-rich proteoglycan                                  | Q6QMY6     | TSKU     | ES       | other           | 1.126   | 0.010   |
| Ig kappa chain V-IV region-like                                           | F1M1R0     | LOC690813| Other    |                 | 1.057   | 0.026   |
| Urinary protein 2                                                         | P81828     |          |          |                 | 1.027   | 0.017   |
| Urinary protein 3                                                         | M0R7P3     |          |          |                 | 1.002   | 0.001   |
| Ig-like domain-containing protein                                         | A0A0G2JXB7 |          |          |                 | 1.001   | 0.005   |
| Urinary protein 2                                                         | P81827     | LOC10036095| Other   |                 | 0.994   | 0.026   |
| H1.2 linker histone, cluster member                                       | A0A0G2KX64 |           |          |                 | 0.984   | 0.032   |
| Ig-like domain-containing protein                                         | M0R7Q2     |           |          |                 | 0.96    | 0.047   |
| Cochlin                                                                   | B1H2S9     | Coch     | Cytoplasm| other           | 0.94    | 0.008   |
| Transcription factor binding to IGHM enhancer 3                          | D3ZAW6     | TFE3     | Nucleus  | TR              | 0.869   | 0.015   |
| Insulin-like growth factor-binding protein 6                              | P35572     | IGFBP6   | ES       | other           | 0.835   | 0.018   |
| Angiogenin                                                                | Q5GAM5     | ANG      | ES       | enzyme          | 0.776   | 0.007   |
| GM2 ganglioside activator                                                 | Q6IN37     | GM2A     | Cytoplasm| enzyme          | 0.772   | 0.023   |
| CDS5 molecule like                                                        | Q4RMT7     | CDSL     | PM       | Tm. Rc.         | 0.768   | 0.020   |
| Similar to BCO49975 protein                                               | F1M6S5     |          |          |                 | -0.71   | 0.039   |
| Mannosidase alpha class 1A member 1                                       | A0A0G2JW29 | MAN1A1   | Cytoplasm| enzyme          | -0.732  | 0.026   |
| Uncharacterised protein                                                   | M0R5J4     |          |          |                 | -0.746  | 0.015   |
| Filamin A                                                                 | C0JPT7     | FLNA     | Cytoplasm| other           | -0.754  | 0.016   |
| NME/NM23 nucleoside diphosphate kinase 2                                  | P19804     | NME2     | Nucleus  | kinase          | -0.76   | 0.026   |
| Ig-like domain-containing protein                                         | M0RDF2     |          |          |                 | -0.762  | 0.009   |
| Paraoxonase 1                                                             | P55159     | PON1     | ES       | phosphatase     | -0.764  | 0.048   |
| Serpin family D member 1                                                  | A0A0G2KX83 | SERPIND1 | ES       | other           | -0.786  | 0.026   |
| RIKEN cDNA 13000170j2 gene                                                | E9PST1     | 13000170j2Rik| ES | other      | -0.811  | 0.022   |
| Cytochrome c, somatic                                                    | P62898     | CYCS     | Cytoplasm| transporter     | -0.812  | 0.020   |
| Tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein zeta | A0A0G2JV65 | YWHAZ    | Cytoplasm| enzyme          | -0.818  | 0.027   |
| Tropomyosin 3                                                             | Q63610     | Tpm3     | Cytoplasm| other           | -0.821  | 0.034   |
| Histidine-rich glycoprotein                                               | A0A0G2KX3G0| Hrg      | Cytoplasm| other           | -0.824  | 0.050   |
| Serpin family A member 6                                                  | P31211     | SERPINA6 | ES       | other           | -0.837  | 0.033   |
| Profilin 1                                                                | P62963     | PFN1     | Cytoplasm| other           | -0.845  | 0.021   |
| Integrin subunit beta 1                                                  | A0A0G2JSK5 | ITGB1    | PM       | Tm. Rc.         | -0.85   | 0.001   |
| Serine protease 3                                                         | D3ZQV0     | PRSS3    | ES       | peptidase       | -0.852  | 0.002   |
| Caveolae associated protein 2                                             | Q66H98     | CAVIN2   | PM       | other           | -0.862  | 0.040   |
| Cofilin 1                                                                 | P45592     | CFL1     | Nucleus  | other           | -0.863  | 0.005   |
| Carboxylesterase 1C                                                       | D3ZGK7     | Ces1c    | ES       | enzyme          | -0.866  | 0.027   |
| Complement component 4 binding protein alpha                              | Q63514     | C4BPA    | ES       | other           | -0.878  | 0.003   |
| Phosphoglycerate kinase 1                                                 | P16617     | PGK1     | Cytoplasm| kinase          | -0.88   | 0.002   |
| FY1N binding protein 1                                                    | D3ZIE4     | FYB1     | Nucleus  | other           | -0.883  | 0.037   |
| Tubulin beta class I                                                      | P69897     | TUBB     | Cytoplasm| other           | -0.888  | 0.015   |
| Thymosin beta 4 X-linked                                                  | P62329     | TMSB10/TMSB4X| Cytoplasm| other      | -0.907  | 0.047   |
| Complement C1s                                                            | G3VL3      | C1S      | ES       | peptidase       | -0.911  | 0.049   |
| Alpha-1-B glycoprotein                                                   | Q9EFP1     | A1BG     | ES       | other           | -0.921  | 0.016   |
| Carboxylesterase 1C                                                       | P10959     | Ces1c    | ES       | enzyme          | -0.951  | 0.043   |
| Inter-alpha-trypsin inhibitor heavy chain 4                               | Q5EBBC0    | ITH4     | ES       | other           | -0.964  | 0.005   |
| Serylglycin                                                              | P04917     | Srgn     | Cytoplasm| other           | -0.981  | 0.012   |
| Cysteine- and glycine-rich protein 1                                      | P47875     | C3RP1    | Nucleus  | other           | -0.984  | 0.022   |
### Table 2 (continued)

#### (a)

| Description                                                                 | UniProt ID | Gene       | Location | Type(s)     | Log10 FC | p - value |
|----------------------------------------------------------------------------|------------|------------|----------|-------------|-----------|-----------|
| Haemoglobin subunit beta-2-like                                            | Q62669     | LOC103694855 | Other    | other       | -1.014    | 0.020     |
| Glutathione peroxidase 3                                                   | A0A0G2X3S1 | GPX3       | ES       | enzyme      | -1.02     | 0.022     |
| Thioredoxin                                                                | R4GNK3     | TXN        | Cytoplasm | enzyme      | -1.034    | 0.003     |
| Ig-like domain-containing protein                                          | F1UD0      |            |          |             | -1.072    | 0.001     |
| Pleckstrin                                                                 | A0A0G2X393 | PLEK       | Cytoplasm | other       | -1.119    | 0.003     |
| Cyclase associated actin cytoskeleton regulatory protein 1                 | Q08163     | CAP1       | PM       | other       | -1.131    | 0.011     |
| Phospholipid transfer protein                                              | E9PS1      | PLTP       | ES       | enzyme      | -1.151    | 0.047     |
| Ceruloplasmin                                                             | G3V7K3     | CP         | ES       | enzyme      | -1.152    | 0.002     |
| Tropomyosin 4                                                              | P09495     | Tpm4       | Cytoplasm | other       | -1.153    | 0.003     |
| Serpin family A member 10                                                 | Q62975     | SERPINA10  | ES       | other       | -1.178    | 0.001     |
| Pleckstrin                                                                | A0A0G2X3K2 | ACTB       | Cytoplasm | other       | -1.211    | 0.020     |
| Tubulin beta 1 class VI                                                   | M0RB86     | TUBB1      | Cytoplasm | other       | -1.217    | 0.011     |
| Transgelin 2                                                               | Q5XF0      | TAGLN2     | Cytoplasm | other       | -1.269    | 0.008     |
| Complement component 4 binding protein beta                                | A0A5CS5    | C4BPB      | ES       | other       | -1.334    | 0.002     |
| Ig-like domain-containing protein                                          | F1LYQ4     |            |          |             | -1.365    | 0.014     |
| Calponin 2                                                                 | D32R9X     | CNN2       | Cytoplasm | other       | -1.389    | 0.017     |
| Deleted in malignant brain tumours 1                                       | Q8C1Z5     | DMBT1      | PM       | Tm. Rc.     | -1.435    | 0.025     |
| Lactate dehydrogenase A                                                   | P04642     | LdhalphaRD1562690 | Cytoplasm | enzyme      | -1.597    | 0.008     |
| Tubulin alpha 4a                                                           | Q5XF6      | TUBA4A     | Cytoplasm | other       | -1.655    | 0.000     |
| RAP1B, member of RAS oncogene family                                       | Q62636     | RAP1B      | Cytoplasm | enzyme      | -1.671    | 0.001     |
| Complement C8 beta chain                                                  | P53314     | C8B        | ES       | other       | -1.743    | 0.013     |
| Actin alpha 1, skeletal muscle                                             | P68136     | ACTA1      | Cytoplasm | other       | -2.257    | 0.011     |
| H2A.Z variant histone 2                                                   | D4AE0C     | H2AZ2      | Nucleus  | other       | -2.287    | 0.003     |

#### (b)

| Description                                                                 | UniProt ID | Gene       | Location | Type(s)     | Log10 FC | p - value |
|----------------------------------------------------------------------------|------------|------------|----------|-------------|-----------|-----------|
| Ig-like domain-containing protein                                          | M0RD98     |            |          |             | 2.871     | 0.004     |
| Ig-like domain-containing protein                                          | M0RL8      |            |          |             | 2.002     | 0.037     |
| Ig-like domain-containing protein                                          | M0RBG6     |            |          |             | 1.849     | 0.010     |
| Ig-like domain-containing protein                                          | F1LYT5     |            |          |             | 1.791     | 0.022     |
| Ig-like domain-containing protein                                          | F1M2W3     |            |          |             | 1.708     | 0.046     |
| Immunoglobulin kappa constant                                             | P01836     | Igkc       | ES       | other       | 1.621     | 0.024     |
| Ig-like domain-containing protein                                          | D32WC1     |            |          |             | 1.591     | 0.029     |
| Ig-like domain-containing protein                                          | F1LW26     |            |          |             | 1.549     | 0.028     |
| Ig-like domain-containing protein                                          | D3Z7P5     |            |          |             | 1.521     | 0.036     |
| Keratin 86                                                                 | A0A0G2X710 | KRT86      | Cytoplasm | other       | 1.301     | 0.012     |
| Ig-like domain-containing protein                                          | A0A0G2X759 |            |          |             | 1.194     | 0.044     |
| Ig-like domain-containing protein                                          | M0RBK4     |            |          |             | 1.16      | 0.032     |
| Keratin 87                                                                 | A7M746     | Krt87      | ES       | other       | 1.154     | 0.045     |
| Lipopolysaccharide binding protein                                         | Q63313     | LBP        | PM       | transporter | 1.02      | 0.001     |
| Insulin-like growth factor-binding protein 4                               | P21744     | IGFBP4     | ES       | other       | 0.984     | 0.050     |
| Glycoprotein V platelet                                                    | G3V9H9     | NEWGENE2724 | Other    | other       | 0.976     | 0.010     |
| Transferrin                                                                | P12346     | TF         | ES       | transporter | 0.904     | 0.015     |
| Carboxypeptidase B2                                                        | Q9EC9V     | CPB2       | ES       | peptidase   | 0.719     | 0.049     |
| Vinculin                                                                   | A0A0G2X8V2 | VCL        | PM       | enzyme      | -0.901    | 0.045     |
| Proteasome 20S subunit alpha 5                                             | P34064     | PSMA5      | Cytoplasm | peptidase   | -0.906    | 0.025     |
| Heat shock protein family A (Hsp70) member 5                                | P06761     | HSPA5      | Cytoplasm | enzyme      | -0.989    | 0.032     |
| Proteasome 20S subunit beta 1                                               | P18421     | PSMB1      | Cytoplasm | peptidase   | -1.111    | 0.002     |
| Coagulation factor X                                                       | Q63207     | F10        | ES       | peptidase   | -1.147    | 0.023     |
| Filamin A                                                                  | C0JPT7     | FLNA       | Cytoplasm | other       | -1.266    | 0.018     |
female group, the proteins are defence/immunity proteins (12), while the translational proteins were the most highly ranked (Fig. 4b). In addition, most proteins were associated with binding, catalytic, or structural molecule activities shown in (Fig. 4c). To determine disease and function, the pool of DEPs (p<0.05, log2 value (|log2x| > 0.7) were selected and analysed using IPA. In this step, the male rats’ selected DEPs showed the upregulation of neutrophil movement and downregulation of viral infections. Simultaneously, the female DEPs showed the downregulation of viral infections and tumour cell line viability (Fig. 4d). These results implied that long-term KRG administration protects the male and female rats from viral infections.

**Discussion**

Numerous studies related to KRG safety only examined its effects when administered for 8–12 wk. Recently, a large-scale clinical trial involving a 6 mo administration of KRG was performed [4]. However, more long-term studies on safety have yet to be conducted because clinical trials involving people are limited by cost and time. In this study, the toxicity of KRG measured during 4, 8, and 12 mo of repeated oral administration to rats was evaluated; analysing the mortality and clinical characteristics revealed no marked difference among all treatment and control groups. Most haematological and blood chemistry parameters showed no significant difference between the control and KRG-treated group. Although significant differences were found in some indicators, all were minor changes within the normal range and had no clinical significance [7]. In addition, there were no significant histopathological changes in the evaluated organs, even though spontaneous or ageing-related findings were observed in the male and female administration groups. Therefore, this study’s results indicate that oral administration of KRG did not produce any significant toxic effects.

In addition, this study attempted to confirm the changes in the ratio of immune cells in the thymus and spleen after administering KRG for 12 mo. Results show that the ratio of NK cells, T cells, and DC cells significantly increased in the male thymus. The ratio of T cells also significantly increased in the female thymus, and the NK cell activity increased in the male spleen. In a recent study, age-dependent alteration of immune cell subtypes in mice, such as a decrease of NK and CD4 T cells, was identified through single-cell profiling of the immune system. Therefore, the results obtained by this study could be evidence that long-term KRG intake has potent anti-immunosenescent effects [8]. A 12-mo-old mouse is considered middle-aged (10–14 mo), equivalent to 38–47 year in humans. Middle age refers to a phase during which senescent changes can be detected in some
biomarkers, and senescence in younger adults can be detected [9]. Presumably, long-term administration of KRG can affect innate, mediated, and acquired immunity in middle-aged rats. Although changes in the immune cells in males compared to females were deemed significant, comparing them at an age range with evident age-related changes might be able to provide more explicit research implications.

Meanwhile, proteomic analysis was performed on blood obtained after 12 mo. The 11-plex TMT proteomic analysis of the sera revealed differentially expressed proteins (DEPs) based on biological function, and the analysis showed most proteins were defence/immunity and binding proteins. A more detailed bioinformatic interpretation showed that viral infection incidences decreased in male and female rat groups when administered with KRG for 12 mo. In male rats, concomitant infections caused by RNA viruses and Human Immunodeficiency Virus (HIV) decreased. The analysis confirmed that CYCS (HGNC:4367), RAP1B (HGNC:9857), MANAa1, and ITGB1 (HGNC:6153) decreased, and GM2A (HGNC:4367) increased, all of which have common functions involved with RNA viruses and HIV infection.

RAP1 is a member of the Ras superfamily of monomeric GTPases closely related to Ras, which regulates several signal pathways involved in cell formation, immune response, polarity, and apoptosis and has two isoforms (RAP1A and RAP1B). Current data suggest that RAP1B is overexpressed in many tumours [10]. In addition, it was reported that the hepatitis B virus (HBV) downregulated microRNA-101 (mir-101) by upregulating RAP1B, which promoted the proliferation and migration of HCC [11]. Meanwhile, ITGB1, also known as CD29, is a cell surface receptor that serves as an important host factor for rabies virus (RABV) infection. The presence of RABV drastically decreased after ITGB1 interfered with RNA knockdown and moderately increased after ITGB1 was overexpressed in cells [12]. Other studies also reported that the downregulation of ITGB1 decreased the number of early infections with human cytomegalovirus, Ebola virus, parvovirus, and reovirus [12]. The GM2 gangloside activator, also known as GM2A, is a lipid transfer protein that stimulates the enzymatic processing of gangliosides and T-cell activation through lipid presentation [13]. Several proteins, including GM2A, are underexpressed in CD4 lymphoblasts after HIV inoculation [14]. In addition, genome-scale siRNAs screening showed GM2A acted as a potential restricting factor for HIV [15]. These reports suggested that their hypoexpression could be associated with a high virus replication rate in human cells. Transgelin (TAGLN) family members, which contains three isotopes, have been identified as actin crosslinking/gelling proteins. Specifically, TAGLN2 (transgelin2 or SM22; HGNC:1154), a putative actin crosslinking/gelling protein, plays an important role in the early stages of HIV-1 infection, as observed in a siRNA analysis. In addition, some reports indicated that TAGLN2 was overexpressed in gastric cancers and hepatocellular carcinomas [16, 17]. All proteins concerning HIV-1 and RNA virus infections and cell infections in the female rats were lower. It was also reported that mutant ATP5F1B (unspecific knockdown) decreased the replication of HSV-1 [18]. In addition, the interference of human ATP5F1B (HGNC:830) and CCT2 (HGNC:1615) mRNA by siRNA decreases the productive infection of HeLa P4/R5 cells of HIV-1 HXB2 [15]. Specifically, a fragment (169–263) from the DHX9 protein increases the infection of MT-2 cells in a cell culture infected with HIV-1 [19]. It also reported that human PSMA5 mRNA interference by siRNA decreases HEK293T cells’ infection caused by HIV-1.

**Conclusion**

This study’s results suggested that long-term KRG administration for 12 mo is considered safe as no notable toxicological changes occurred. The study confirmed that the immune cell counts increased, and the proteins’ changes were related to reducing infections.

**Abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| ABC          | Ammonium bicarbonate. |
| A/G          | Albumin-Globulin ratio. |
| AGC          | Automatic Gain Control. |
| ALB          | Albumin. |
| ALP          | Alkaline phosphatase. |
| ALT          | Alanine aminotransferase. |
| AST          | Aspartate aminotransferase. |
| BCA          | Bicinchoninic acid. |
| BUN          | Blood urea nitrogen. |
| CHO          | Total cholesterol. |
| CID          | Collision-Induced Dissociation. |
| CPK          | Creatine phosphokinase. |
| CRE          | Creatine. |
| DEPs         | Differentially Expressed Proteins. |
| DTT          | Dithiothreitol. |
| EDTA         | Ethylenediaminetetraacetic acid. |
| FDR          | False Discovery Rate. |
| GLU          | Glucose. |
| H & E        | Haematoxylin and Eosin. |
| Hb           | Haemoglobin. |
| HCD          | Higher-energy Collision Dissociation. |
| Hct          | Haematocrit. |
| IAA          | Iodoacetamide. |
| IPA          | Ingenuity Pathway Analysis. |
| KRG          | Korean Red Ginseng. |
| MCH          | Mean Corpuscular Haemoglobin. |
| MCHC         | Mean Corpuscular Haemoglobin Concentration. |
| MCV          | Mean Corpuscular Volume. |
| NCE          | Normalised Collision Energy. |
| PLT          | Platelet. |
| RABV         | Rabies virus. |
| RBC          | Red Blood Cell. |
| RPLC         | Reverse-Phase Liquid Chromatography. |
| SPS          | Synchronous Precursor Selection. |
| TAGLN        | Transgelin. |
| TG           | Triglyceride. |
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12906-022-03736-5.

Supplementary Material 1
Supplementary Material 2
Supplementary Material 3
Supplementary Material 4
Supplementary Material 5
Supplementary Material 6

Acknowledgements
None.

Authors’ contributions
Soo Kyung Park, Sung-Won Kim: Methodology, Formal analysis, Investigation, Resources, Writing–review and editing, Visualisation; Hwi Won Seo: Methodology, Investigation, Resources; Sun Hee Hyun: Formal analysis, Visualisation; Jong-Su Kyung: Investigation, Resources; Soo-Hyun Youn: Formal analysis, Investigation, Visualisation; Seung Ho So: Conceptualisation, Methodology, Soo Kyung Park: Writing–review and editing, Chae-Kyu Park: Conceptualisation, Supervision; Eugene C. Yi: Formal analysis, Data curation; Chang-Kyun Han: Supervision, Project Administration; Yong Yook Lee: Software, Validation, Investigation, Data curation, Writing–original draft preparation, Project administration. The authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Availability
The datasets and mass spectrometry proteomics data generated and analysed during the current study have been deposited in the ProteomeXchange Consortium via the PRIDE [20] partner repository. The datasets used during the current study are available from the corresponding author on reasonable request [dataset identifier PXD032036].

Declarations
Ethics approval and consent to participate
Ethical approval was obtained from the Institutional Animal Care and Use Committee of the Korean Ginseng Research Institute (Daejeon, Republic of Korea) following the Guide for the Care and Use of Laboratory Animals [KT&G 18–20].

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 14 December 2021 / Accepted: 16 September 2022
Published online: 04 November 2022

References
1. Wang S. Leveraging budding yeast Saccharomyces cerevisiae for discovering aging modulation substances for functional food. Funct Foods Health Dis. 2019;9(5):297–311. https://doi.org/10.1016/j.ffhd.2019.05.575.
2. Galanakis CM. The food systems in the era of the coronavirus (COVID-19) pandemic crisis. Foods. 2020;9(4). https://doi.org/10.3390/foods9040523.
3. Tadesse SA, Emire SA. Production and processing of antioxidant bioactive peptides: A driving force for the functional food market. Helyon. 2020;6(8):e04765. https://doi.org/10.1016/j.helyon.2020.e04765.
4. Song SW, Kim HN, Shim JY, Yoo BY, Kim DH, Lee SH, et al. Safety and tolerability of Korean Red Ginseng in healthy adults: A multicenter, double-blind, randomized, placebo-controlled trial. J Ginseng Res. 2018;42(4):571–6. https://doi.org/10.1016/j.jgr.2018.07.002.
5. Kim YS, Woo JY, Han CK, Chang JM. Safety analysis of Panax ginseng in randomized clinical trials: A systematic review. Med (Basel). 2015;2(2):106–26. https://doi.org/10.3390/medicines2020106.
6. Kim GK, Choi S, Lee J, Hong YH, Jeong D, Yoon K, et al. Sgc is a prime target inhibited by Celts choisiniensis methanol extract in its anti-inflammatory action. Evid Based Complement Alternat Med. 2018;2018:299038. https://doi.org/10.1155/2018/299038.
7. Lee JM, Lee MA, Do HN, Song YL, Bae RJ, Lee HY, et al. Historical control data from 13-week repeated toxicity studies in C57BD (SD) rats. Lab Anim Res. 2018;28(2):115–21. https://doi.org/10.5625/lar.2012.28.2.115.
8. Krishnarajah S, Ingelfinger F, Friebel E, Cansever D, Amorim A, Andreadou M, et al. Single-cell profiling of immune system alterations in lymphoma, barrier and solid tissues in aged mice. Nat Aging. 2022;2(1):74–89. https://doi.org/10.1038/s43587-021-00148-x.
9. Flurkey K, Currer J, Harrison D. Mouse models in aging research. In: Fox JG, Quimby FW, editors. The mouse in biological research. 2nd ed. Cambridge: Academic Press, 2007. pp. 63–72.
10. Zhang L, Cui M, Song L, Zhang M, Zhang J. Function, significance, and regulation of Rap1b in malignancy. Crit Rev Eukaryot Gene Expr. 2019;29(2):151–60. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2019025997.
11. Sheng Y, Ding S, Chen K, Chen J, Wang S, Zou C, et al. Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis. Biochem Cell Biol. 2014;92(2):152–62. https://doi.org/10.1139/bcb-2013-0128.
12. Shuai L, Wang J, Zhao G, Wen Z, Ge J, He X, et al. Integrin β1 promotes peripheral entry by rabies virus. J Virol. 2020;94(2):e01819-19. https://doi.org/10.1128/JVI.01819-19.
13. Keller CW, Freigang S, Lünemann JD. Reciprocal crosstalk between dendritic cells and natural killer T cells: Mechanisms and therapeutic potential. Front Immunol. 2017;8:570. https://doi.org/10.3389/fimmu.2017.00570.
14. Puissant-Lubran B, Apoil P-A, Gleizes A, Forestier L, Julien R, Winterton P, et al. Modulation of gene expression in CD4+ T lymphocytes following in vitro HIV infection: A comparison between human and chimpanzee. Virusdisease. 2008;4(5):495–504. https://doi.org/10.1016/j.virusd.2008.10.004.
15. Zhang L, Zhao Y, Li J, Zou Y, Li Y, Zhang C-Q, et al. Identification of marker genes in virus infection: A comparison between human and chimpanzee. Virusdisease. 2005;9(2):929–34. https://doi.org/10.1016/j.virusd.2005.04.001.
16. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe. 2012;28(2):115–21. https://doi.org/10.1016/j.chom.2008.10.004.
17. Shi Y, Li Y, Zhang L, Sun W-S, Li Y, Zhang C-Q, et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer. 2005;92(5):929–34. https://doi.org/10.1038/sj.bjc.6602460.
18. Zheng S-Q, Li Y-X, Zhang Y, Li X, Tang H. MiR-101 regulates HSV-1 replication by targeting ATP5B. Antivir Res. 2011;89(3):219–26. https://doi.org/10.1016/j.antiviral.2011.01.008.
19. Sadler AJ, Latchoumanin O, Hawkes D, Mak J, Williams BRG. An antiviral response directed by PKR phosphorylation of the RNA helicase A. PLoS Pathog. 2009;5(2):e1000311. https://doi.org/10.1371/journal.ppat.1000311.
20. Perez-Riverol Y, Bai J, Bandla C, Garcia-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. (2022). The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543–D552. https://doi.org/10.1093/nar/gkab1038.